{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-001993","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.256444+00:00","generated_at":"2026-06-04T04:25:23.098985+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sunshine Biopharma reports 2023 sales $24.1M, loss per share improves to -$0.19","bullets":["Sales grew to $24,092,787 in 2023 from $4,345,603 in 2022; average quarter-over-quarter growth of 14%.","Net loss narrowed to $4,506,044 from $26,744,440; loss per share improved to -$0.19 from -$1.76.","Gross profit rose to $8,339,171 from $1,696,575; G&A expenses reduced to $13.1M from $28.7M.","Completed $5M private placement; repurchased 513,723 shares for $541,143.","Two proprietary drugs advanced to animal testing; IND-enabling studies for Adva-27a halted in November 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-001993","json":"https://secwatch.observer/filing/0001683168-24-001993.json","markdown":"https://secwatch.observer/filing/0001683168-24-001993.md","text":"https://secwatch.observer/filing/0001683168-24-001993.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001993/0001683168-24-001993-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001993/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:25:23.098985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ea105e52f450583fddfb816cf33801569faf770","claim":"Sunshine Biopharma Inc. reported the fiscal year ended December 31, 2023 results: revenue $ 24,092,787, net income $ 4,506,044, EPS negative $0.19 per share.","evidence_excerpt":"The following are key items contained in the Company’s Income Statement included in the 2023 10-K: 2023 2022 Sales $ 24,092,787 $ 4,345,603 Gross Profit $ 8,339,171 $ 1,696,575 General & Administrative Expenses $ 13,124,470 $ 28,697,325 Goodwill impairment $ – $ 18,326,719 Net Loss $ 4,506,044 $ 26,744,440","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001993/0001683168-24-001993-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$ 24,092,787"},{"label":"Net income","value":"$ 4,506,044"},{"label":"EPS","value":"negative $0.19 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}